Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Abiraterone in Metastatic Prostate Cancer
NCT06193993Phase 1Active, not recruiting
- Sponsor
- National University Hospital
- Start
- Nov 2021
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Abiraterone Acetate Tablets (I) in metastatic castration-resistant prostate cancer (mCRPC) and prostate cancer (PCa), sponsored by National University Hospital. Primary endpoint: Percentage of patients with greater than or equal to 50 percent decrease in Prostate Specific Antigen (PSA) levels at 12 weeks. Started Nov 2021; status: active, not recruiting.
02
Drugs
Abiraterone Acetate Tablets (I)
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06193993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06193993.